Conference dates: OCTOBER 10-12, 2023
Location: Hall 1, Messe Basel, Basel, Switzerland
Title: High-throughput antibody discovery and screening at LifeArc
Speaker: Sharandip Nijjar, PhD, Senior Scientist, LifeArc
Date: Wednesday, October 11, 2023
Time: 15:00 – 15:20 CEST
Location: Protein Engineering Track, Theatre 12
Abstract: At LifeArc we carry out high-throughput antibody screening to discover, characterise and deliver therapeutic monoclonal antibodies. We perform detailed kinetic profiling, epitope specificity, cross reactivity, functional binding and a suite of developability assessment assays to ensure successful downstream development of our lead molecule. We are always looking at ways to innovate our screening platform to ensure we remain at the cutting edge of technology, enabling us to characterise more molecules in a more efficient process. Recently we have purchased the Carterra LSA and here we will share the evolution of our screening platform and how the LSA will enhance our discovery workflow.
Poster 1: Large-scale characterization of drug candidates against transmembrane receptors using HT-SPR
Presenter: Judicaël Parisot, PhD, Head, Applications Science – Europe, Carterra
Abstract: Membrane targets make up a substantial part of the overall “undruggable” therapeutic space that has recently garnered widespread interest. Despite encouraging improvements in the tools to screen for therapeutics against membrane-bound targets, there are still many practical limitations owing to the challenges of working with proteins that are not highly stable outside of the cell membrane environment. High-throughput surface plasmon resonance (HT-SPR) is a powerful technique that is transforming characterization workflows and enabling a greater breadth and depth of information for drug candidates. Here we demonstrate the ability to quantitatively assess binding kinetics for panels of antibodies against membrane receptors in several formats. This workflow highlights opportunities to perform detailed binding characterization for up to thousands of drug candidates in parallel.